MNOV
MediciNova, Inc. [MNOV] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
MNOV Stock Summary
Top 10 Correlated ETFs
MNOV
Top 10 Correlated Stocks
MNOV
In the News
MNOV Financial details
Company Rating
Neutral
Market Cap
77M
Income
-8.53M
Revenue
1000M
Book val./share
1.27
Cash/share
1.04
Dividend
-
Dividend %
-
Employees
13
Optionable
No
Shortable
Yes
Earnings
10 May 2024
P/E
-7.93
Forward P/E
-
PEG
1.98
P/S
0.08
P/B
1.16
P/C
1.34
P/FCF
-6.86
Quick Ratio
18.74
Current Ratio
18.92
Debt / Equity
0
LT Debt / Equity
-
-
-
EPS (TTM)
-0.17
EPS next Y
-
EPS next Q
-
EPS this Y
-41.38%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
185.71%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-50%
Inst Own
6.07%
Inst Trans
0.55%
ROA
-14%
ROE
-14%
ROC
-17.7%
Gross Margin
100%
Oper. Margin
-116%
Profit Margin
-1%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.26-2.66
52W High
-30.25%
52W Low
+39.5%
RSI
45
Rel Volume
0.29
Avg Volume
51.37K
Volume
15.1K
Perf Week
-10.58%
Perf Month
-0.36%
Perf Quarter
-27.34%
Perf Half Y
-29.9%
-
-
-
-
Beta
0.687
-
-
Volatility
0.07%, 0.07%
Prev Close
-0.36%
Price
1.395
Change
-1.76%
MNOV Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0.08 | 0 | 0.02 | |
| Net income per share | -0.3 | -0.31 | -0.21 | -0.29 | -0.17 | |
| Operating cash flow per share | -0.21 | -0.24 | -0.19 | -0.26 | -0.15 | |
| Free cash flow per share | -0.21 | -0.24 | -0.19 | -0.26 | -0.15 | |
| Cash per share | 1.48 | 1.35 | 1.47 | 1.19 | 1.04 | |
| Book value per share | 1.74 | 1.61 | 1.72 | 1.43 | 1.27 | |
| Tangible book value per share | 1.4 | 1.28 | 1.43 | 1.14 | 0.98 | |
| Share holders equity per share | 1.74 | 1.61 | 1.72 | 1.43 | 1.27 | |
| Interest debt per share | -39.25 | -38.15 | 0 | -0.01 | 0 | |
| Market cap | 290.89M | 233.61M | 130.24M | 100.54M | 73.57M | |
| Enterprise value | 227.5M | 173.76M | 58.94M | 82.19M | 22.79M | |
| P/E ratio | -22.48 | -16.86 | -12.85 | -7.15 | -8.58 | |
| Price to sales ratio | 0 | 0 | 32.26 | 0 | 73.57 | |
| POCF ratio | -31.88 | -21.58 | -13.88 | -7.79 | -9.9 | |
| PFCF ratio | -31.84 | -21.51 | -13.84 | -7.78 | -9.87 | |
| P/B Ratio | 3.88 | 3.28 | 1.56 | 1.43 | 1.18 | |
| PTB ratio | 3.88 | 3.28 | 1.56 | 1.43 | 1.18 | |
| EV to sales | 0 | 0 | 14.6 | 0 | 22.79 | |
| Enterprise value over EBITDA | -16.24 | -12.27 | -5.78 | -5.63 | -2.31 | |
| EV to operating cash flow | -24.93 | -16.05 | -6.28 | -6.37 | -3.07 | |
| EV to free cash flow | -24.9 | -16 | -6.26 | -6.36 | -3.06 | |
| Earnings yield | -0.04 | -0.06 | -0.08 | -0.14 | -0.12 | |
| Free cash flow yield | -0.03 | -0.05 | -0.07 | -0.13 | -0.1 | |
| Debt to equity | -22.62 | -23.75 | 0 | 0 | 0 | |
| Debt to assets | -21.39 | -22.46 | 0 | 0 | 0 | |
| Net debt to EBITDA | 4.53 | 4.23 | 7 | 1.26 | 5.14 | |
| Current ratio | 28.86 | 27.67 | 25.42 | 18.51 | 15.61 | |
| Interest coverage | 0 | 0 | 0 | 26.01 | 0 | |
| Income quality | 0.71 | 0.78 | 0.93 | 0.92 | 0.87 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 1.42 | 0 | 5.24 | |
| Research and developement to revenue | 0 | 0 | 2.11 | 0 | 5.66 | |
| Intangibles to total assets | 0.18 | 0.19 | 0.16 | 0.19 | 0.22 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | -0.01 | 0 | -0.02 | |
| Capex to depreciation | -0.47 | -1.71 | -1.1 | -0.28 | -1.05 | |
| Stock based compensation to revenue | 0 | 0 | 0.43 | 0 | 0.71 | |
| Graham number | 3.42 | 3.36 | 2.84 | 3.04 | 2.24 | |
| ROIC | 0.01 | 0.01 | -0.12 | -0.21 | -0.16 | |
| Return on tangible assets | -0.2 | -0.23 | -0.14 | -0.24 | -0.17 | |
| Graham Net | 1.38 | 1.26 | 1.39 | 1.11 | 0.96 | |
| Working capital | 62.08M | 58.52M | 69.18M | 55.8M | 47.9M | |
| Tangible asset value | 60.49M | 56.93M | 69.28M | 55.84M | 47.98M | |
| Net current asset value | 59.99M | 56.62M | 68.28M | 55.07M | 47.28M | |
| Invested capital | -22.62 | -23.75 | 0 | 0 | 0 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 534.04K | 533.98K | 509.68K | 413.69K | 714.29K | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 6.88K | 10.55K | 0 | 729.65 | 18.06K | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0.05 | 0.03 | 0 | 0.5 | 0.02 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | -0.17 | -0.19 | -0.12 | -0.2 | -0.14 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q3
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 20.39 | 0 | |
| Net income per share | -0.06 | -0.06 | -0.06 | -0.01 | -0.04 | |
| Operating cash flow per share | -0.08 | -0.06 | -0.05 | -0.03 | -0.01 | |
| Free cash flow per share | -0.08 | -0.06 | -0.05 | -0.03 | -0.01 | |
| Cash per share | 1.19 | 1.13 | 1.08 | 1.05 | 1.04 | |
| Book value per share | 1.43 | 1.38 | 1.33 | 1.32 | 1.27 | |
| Tangible book value per share | 1.14 | 1.09 | 1.04 | 1.02 | 0.98 | |
| Share holders equity per share | 1.43 | 1.38 | 1.33 | 1.32 | 1.27 | |
| Interest debt per share | 0 | 0.01 | 0.01 | 0.01 | 0 | |
| Market cap | 100.54M | 105.94M | 112.81M | 102.51M | 73.57M | |
| Enterprise value | 82.2M | 51.31M | 60.13M | 51.67M | 22.79M | |
| P/E ratio | -8.37 | -9.22 | -9.82 | -35.44 | -8.93 | |
| Price to sales ratio | 0 | 0 | 0 | 0.1 | 0 | |
| POCF ratio | -25.09 | -33.34 | -47.34 | -74.74 | -147.42 | |
| PFCF ratio | -25.06 | -33.34 | -46.97 | -74.59 | -147.42 | |
| P/B Ratio | 1.43 | 1.56 | 1.73 | 1.59 | 1.18 | |
| PTB ratio | 1.43 | 1.56 | 1.73 | 1.59 | 1.18 | |
| EV to sales | 0 | 0 | 0 | 0.05 | 0 | |
| Enterprise value over EBITDA | -25.47 | -17.34 | -18.25 | -0.05 | -9.17 | |
| EV to operating cash flow | -20.51 | -16.15 | -25.23 | -37.67 | -45.66 | |
| EV to free cash flow | -20.49 | -16.15 | -25.04 | -37.6 | -45.66 | |
| Earnings yield | -0.03 | -0.03 | -0.03 | -0.01 | -0.03 | |
| Free cash flow yield | -0.04 | -0.03 | -0.02 | -0.01 | -0.01 | |
| Debt to equity | 0 | 0.01 | 0.01 | 0.01 | 0 | |
| Debt to assets | 0 | 0.01 | 0.01 | 0.01 | 0 | |
| Net debt to EBITDA | 5.69 | 18.46 | 15.99 | 0.04 | 20.44 | |
| Current ratio | 18.51 | 20.64 | 18.97 | 18.92 | 15.61 | |
| Interest coverage | 8.45 | 64.79 | 0 | 0 | 0 | |
| Income quality | 1.34 | 1.09 | 0.83 | 1.9 | 0.24 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 1.35 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0.79 | 0 | |
| Intangibles to total assets | 0.19 | 0.2 | 0.21 | 0.21 | 0.22 | |
| Capex to operating cash flow | 0 | 0 | 0.01 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | -1.16 | 0 | -3.72 | -0.48 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 1.4 | 1.35 | 1.32 | 0.66 | 1.1 | |
| ROIC | -0.05 | -0.04 | -0.04 | 27.52K | -0.03 | |
| Return on tangible assets | -0.05 | -0.05 | -0.05 | -0.01 | -0.04 | |
| Graham Net | 1.11 | 1.06 | 1.01 | 0.99 | 0.96 | |
| Working capital | 55.8M | 53.32M | 50.7M | 50.19M | 47.9M | |
| Tangible asset value | 55.84M | 53.33M | 50.78M | 50.27M | 47.98M | |
| Net current asset value | 55.07M | 52.63M | 49.98M | 49.53M | 47.28M | |
| Invested capital | 0 | 0.01 | 0.01 | 0.01 | 0 | |
| Average receivables | 0 | 0 | 0 | 500K | 500K | |
| Average payables | 488.68K | 504.86K | 566.64K | 642.56K | 870.42K | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0.09 | 0 | |
| Days payables outstanding | 797.42 | 981.95 | 911.69 | 11.63K | 16.45K | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 1000 | 0 | |
| Payables turnover | 0.11 | 0.09 | 0.1 | 0.01 | 0.01 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | -0.04 | -0.04 | -0.04 | -0.01 | -0.03 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
MNOV Frequently Asked Questions
What is MediciNova, Inc. stock symbol ?
MediciNova, Inc. is a US stock , located in La jolla of Ca and trading under the symbol MNOV
What is MediciNova, Inc. stock quote today ?
MediciNova, Inc. stock price is $1.395 today.
Is MediciNova, Inc. stock public?
Yes, MediciNova, Inc. is a publicly traded company.
Company Profile
- Volume Average 51.37K
- Market Capitalization 77M
- Employee 13
- CEO Dr. Yuichi Iwaki M.D., Ph.D.
- Headquarters La Jolla,CA,US
- IPO Date 2006-12-08
-
Website
https://www.medicinova.com 
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction. Its product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic diseases, including nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. The company has collaboration agreements with Kissei Pharmaceutical Co., Ltd.; Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals Ltd.; and Meiji Seika Kaisha Ltd. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.
